Hypertension referrals from community pharmacy to general practice: Multivariate logistic regression analysis of 131 419 patients

British Journal of General Practice

Volumn 68, Issue 673, 2018, Pages e541-e550

  Albasri, Ali ^a   Prinjha, Suman ^a   McManus, Richard J ^a   Sheppard, James P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

General practice; Hypertension; Logistic regression; New medication; Pharmacists; Referral

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; ENGLAND; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PATIENT-REPORTED OUTCOME; PHARMACIST; PHARMACY; PREDICTION; PRESCRIPTION; VERY ELDERLY; EPIDEMIOLOGY; GENERAL PRACTICE; MEDICATION COMPLIANCE; MIDDLE AGED; ODDS RATIO; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PHARMACY (SHOP); PROFESSIONAL STANDARD; PUBLIC RELATIONS; STATISTICAL MODEL;

AGED; ANTIHYPERTENSIVE AGENTS; COMMUNITY PHARMACY SERVICES; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; GENERAL PRACTICE; HUMANS; HYPERTENSION; INTERPROFESSIONAL RELATIONS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); PROFESSIONAL ROLE; REFERRAL AND CONSULTATION;

EID: 85052714193     PISSN: 09601643     EISSN: 14785242     Source Type: Journal    
DOI: 10.3399/bjgp18X697925     Document Type: Article

References (21)

1. Pharmaceutical Services Negotiating Committee. New Medicine Service. PSNC, 2011. http://psnc.org.uk/services-commissioning/advanced-services/nms/ (accessed 14 Jun 2018).
2. Elliott RA, Boyd MJ, Salema NE, et al. Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service. BMJ Qual Saf 2016; 25(10): 747–758.
3. Public Health England. Tackling high blood pressure. From evidence into action. 2014. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/527916/Tackling_high_blood_pressure.pdf (accessed 19 Jun 2018).
4. Hobbs FDR, Bankhead C, Mukhtar T, et al. Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007–14. Lancet 2016; 387(10035): 2323–2330.
5. Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomised controlled trials. Br J Clin Pharmacol 2014; 78(6): 1238–1247.
6. Tan ECK, Stewart K, Elliott RA, George J. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Soc Adm Pharm 2014; 10(4): 608–622.
7. Mehuys E, Van Bortel L, De Bolle L, et al. Self-medication of upper gastrointestinal symptoms: a community pharmacy study. Ann Pharmacother 2009; 43(5): 890–898.
8. Curley LE, Moody J, Gobarani R, et al. Is there potential for the future provision of triage services in community pharmacy? J Pharm Policy Pract 2016; 9: 29.
9. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. CG127. London: NICE, 2011. https://www.nice.org.uk/guidance/cg127 (accessed 14 Jun 2018).
10. Lamina C, Sturm G, Kollerits B, Kronenberg F. Visualizing interaction effects: a proposal for presentation and interpretation. J Clin Epidemiol 2012; 65(8): 855–862.
11. Gupta P, Patel P, Strauch B, et al. Risk factors for non-adherence to antihypertensive treatment. Hypertension 2017; 69(6): 1113–1120.
12. Jokisalo E, Kumpusalo E, Enlund H, et al. Factors related to non-compliance with antihypertensive drug therapy. J Hum Hypertens 2002; 16(8): 577–583.
13. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 2016; 34(10): 1921–1932.
14. Lasserson DS, Buclin T, Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart 2011; 97(21): 1771–1775.
15. Albasri A, O’Sullivan JW, Roberts NW, et al. A comparison of blood pressure in community pharmacies with ambulatory, home, and general practitioner office readings. J Hypertens 2017; 35(10): 1919–1928.
16. McManus RJ, Mant J, Bray EP, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 2010; 376(9736): 163–172.
17. McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA 2014; 312(8): 799–808.
18. Robins LS, Jackson JE, Green BB, et al. Barriers and facilitators to evidence-based blood pressure control in community practice. J Am Board Fam Med 2013; 26(5): 539–557.
19. Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 2008; 299(24): 2857–2867.
20. Health and Social Care Information Centre. General practice trends in the UK to 2015. 2016. http://content.digital.nhs.uk/media/21726/General-Practice-Trendsin-the-UK-to-2015/pdf/General_Practice_Trends_in_the_UK_to_2015.pdf (accessed 14 Jun 2018).
21. National Institute for Health and Clinical Excellence. Quality and Outcomes Framework programme: NICE cost impact statement. Indicator area: hypertension. 2011. https://www.nice.org.uk/Media/Default/standardsand-indicators/qof%20indicator%20key%20documents/NM37%20cost%20statement.pdf (accessed 19 Jun 2018).